• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2023.18009

Bioinformational and clinical aspects of identificationof differentially expressed genes by tumor cells in endometrialcarcinoma and rare forms of uterine body cancer

[Original research] [Oncology]
Oleg Kit; Nadezhda Vitalievna Kovalenko; Alexey Maksimov; Ekaterina Verenikina;

The analysis of data on differential gene expression with the isolation of the main signaling pathways in endometrial carcinoma and rare forms of cancer of the uterine body was carried out in the article using of bioinformation technologies and, through subsequent genetic and histological studies, the expression activity of the identified genes was compared with the morphological type of tumor. Real-time PCR was used to assess gene expression in tumor cells. It was found that the expression activity of genes differed depending on the histological type of the uterine body cancer. Overexpression of genes CDKN2A, L1CAM, CLDN4, ERBB2, UBE2C, TNNT1, PAX8, STK15, BUB1 in malignant epithelial tumors of uterine body cancer is associated with a high-grade phenotype. In serous cancer of the uterine body, the genes CDKN2A, L1CAM, ERBB2, UBE2C, TNNT1, STK15, BUB1 are expressed greater, and in clear cell carcinoma – more expressed the genes CLDN4 and PAX8. The introduction of the molecular genetic classification of rare forms of uterine cancer increases the efficiency of prognosis and personification of the treatment of oncological pathology.

Download

References:
1.Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2019 godu. Ed. A. D. Kaprin, V. V. Starinskiy, A. O. Shahzadov. Moscow: MNIOI named after P. A. Herzen is a branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia, 2020. (In Russ.).
2. Nechushkina V. M., Den’gina N. V., Kolomiec L. A., Kravec O. A., Morhov K. Yu. [et al.]. Practical recommendations for the treatment of uterine body cancer and uterine sarcomas. Zlokachestvennye opuholi: Practical Recommendations. RUSSCO. 2018;3s2(8):190-203. (In Russ.). https://doi.org/10.18 027 / 2224-5057-2018-8-3s2-190-203
3. Lakhwani P., Agarwal P., Goel A., Nayar N., Pande P., Kumar K. High-grade endometrial cancer-behaviour and outcomes at a tertiary cancer centre. Indian J. Surg. Oncol. 2019;10(4):662-667. https://doi.org/10.1007/s13193-019-00970-1
4. Vtorushin S. V., Malykh R. D. Modern prerequisites for the molecular genetic classification of endometrial cancer. Arhiv patologii. – Archive of pathology. 2017;(3):57-62. (In Russ.). https://doi.org/10.17116/patol201779357-62
5. Kit O. I., Vodolazhsky D. I., Kutilin D. S., Moiseenko T. I., Nikitin I. S., Frantsyants E. M. Changes in the expression of estrogen-regulatory genes during malignancy of the tissues of the uterine body. Kubanskij nauchnyj medicinskij vestnik. – Kuban Scientific Medical Bulletin. 2016;(2):84-89. (In Russ.). https://doi.org/10.25207/1608-6228-2016-2-84-90
6. McDonald M. E., Bender D. P. Endometrial cancer. obesity, genetics, and targeted agents. Obstet. Gynecol. Clin. North Am. 2019;46(1):89-105. https://doi.org/10.1016/j.ogc.2018.09.006
7. Talhouk A., McConechy M. K., Leung S. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802-813. https://doi.org/10.1002/cncr.30496
8. Ung M. H., Liu C. C., Cheng C. Integrative analysis of cancer genes in a functional interactome. Sci. Rep. 2016;6:29228. https://doi.org/10.1038/srep29228
9. Gryaznov S. A. Bioinformatics perspectives. Mezhdunarodnyj zhurnal gumanitarnyh i estestvennyh nauk. – Int. J. Human. Nat. Sci. 2021;6-2(57):100-102. (In Russ.).
10. Pereginya O. V., Lutsenko T. M. Тranslation medicine, biomedicine and medical biotechnology: the transition to personalized medicine. Biotechnol. Acta. 2020;13(2):5-11. https://doi.org/10.15407/biotech13.02.005
11. Wujcicka W., Zajac A., Szyllo K., Smolarz B., Romanowicz H., Stachowiak G. Association of SNPs in CDKN2A (P14ARF) tumour suppressor gene with endometrial cancer in postmenopausal women. In Vivo. 2020;34(2):943-951. https://doi.org/10.21873/invivo.11862
12. Tang H., Jiang L., Zhu C., Liu R., Wu Y. [et al.]. Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Oncogene. 2019;38(17):3119-3133. https://doi.org/10.1038/s41388-018-0648-7
13. Guo J., Wu Y., Du J., Yang L., Chen W. [et al.]. Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression. Oncogenesis. 2018;7:49-64. https://doi.org/10.1038/s41389-018-0054-6
14. Zhang H.-Q., Zhao G., Ke B., Ma G., Liu G.-L. [et al.]. Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. Eur. Rev. Med. Pharmacol. Sci. 2018;22:1665-1671. https://doi.org/10.26355/eurrev_201803_14578
15. Da Cruz Paula A., DeLair D. F., Ferrando L., Fix D. J., Soslow R. A. [et al.]. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecol. Oncol. 2021;161(2):535-544. https://doi.org/10.1016/j.ygyno.2021.02.015
16. Hao Y. H., Yu S. Y., Tu R. S., Cai Y. Q. TNNT1, a prognostic indicator in colon adenocarcinoma, regulates cell behaviors and mediates EMT process. Biosci. Biotechnol. Biochem. 2020;84(1):111-117. https://doi.org/10.1080/09168451.2019.1664891
17. Koumarianou P., Goméz-López G., Santisteban P. Pax8 controls thyroid follicular polarity through cadherin16. J. Cell Sci. 2017;130(1):219-231. https://doi.org/10.1242/jcs.184291
18. Shan W., Mercado-Uribe I., Zhang J., Rosen D., Zhanq S. [et al.]. Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle. 2012;11(11):2107-2113. https://doi.org/10.4161/cc.20544

Keywords: endometrial adenocarcinoma, serous uterine cancer, clear cell cancer of the uterine body, differentially expressed genes, bioinformatics analysis